<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153757">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098318</url>
  </required_header>
  <id_info>
    <org_study_id>AT005230</org_study_id>
    <secondary_id>R21AT005230</secondary_id>
    <nct_id>NCT01098318</nct_id>
  </id_info>
  <brief_title>Rhodiola Rosea Therapy of Major Depressive Disorder</brief_title>
  <official_title>Rhodiola Rosea Therapy of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior research has shown that Rhodiola rosea may be an effective, short-term,
      anti-depressant therapy. This study will examine the anti-depressant effect of Rhodiola
      rosea vs. a conventional, anti-depressant drug in the treatment of major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will study the antidepressant action of R. rosea in patients with MDD. Depression affects
      more than a billion people world wide, and is now recognized as one of the most disabling
      medical conditions. It accounts for more than 11% of the total disease burden worldwide, and
      can result in devastating consequences and functional impairment exceeded only by that of
      cancer and cardiovascular disease. It results in substantial social, occupational, and
      personal disability and in increased medical co-morbidity and death by suicide. It is
      considered to be a multi-systemic disorder characterized by neurotransmitter,
      neuroendocrine, immunologic, and autonomic, and infectious disturbances. Although the
      development of antidepressant drug therapy has simplified the treatment of MDD, a
      substantial segment of the world's population remains untreated for economic, cultural, or
      personal reasons. As a result, many individuals seek CAM for relief of their symptoms. The
      identification of effective CAM therapies for MDD is of public health relevance. R. rosea
      belongs to the family Crassulaceae, and has a long history as a folk remedy for enhancing
      physical and emotional endurance. Its adaptogen, or preventive, properties have also led to
      its use in treating cancer, infection, depression, and other nervous system disorders.
      Several animal and human studies suggest that R. rosea may have antidepressant properties.
      For specific aim #1, we will ask: Is R. rosea a safe and effective short-term therapy (vs.
      sertraline and placebo) for patients with MDD?&quot; To answer this question, patients meeting
      DSM IV criteria for mild to moderate MDD will be enrolled in a 12-week, randomized,
      double-blind, placebo-controlled, parallel group, dose-escalation study of R. rosea extract
      340-1,360 mg daily vs. sertraline 50-200 mg daily. The primary outcome measure will be
      change over time in the 17-item Hamilton Depression Rating score. We hypothesize that R.
      rosea will have superior efficacy vs. placebo and comparable efficacy vs. sertraline. For
      specific aim #2, we will ask: Does R. rosea therapy result in a favorable tolerability and
      quality of life (QOL) profile vs. sertraline and placebo? To answer this question, we will
      obtain safety and QOL measures across treatment conditions that include: (i) frequency,
      duration, and severity of adverse events, (ii) frequency of serious adverse events, (iii)
      frequency of dosage reduction, (iv) frequency of treatment discontinuation, and (v) QOL and
      sexual performance measures. We hypothesize that R. rosea will have a superior tolerability
      profile vs. sertraline, and similar tolerability vs. placebo. We further hypothesize that R.
      rosea will have superior QOL and sexual performance ratings vs. sertraline and placebo.
      Results from this study will be used to inform future research hypotheses and to estimate
      the effect size necessary to power a future, large scale study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depressive Symptoms as Measured by the Hamilton Depression Rating Scale (17-items) at Week 8 and Week 12.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hamilton Depression Rating Scale (HAM-D) is a validated, clinician-rated instrument for ascertaining the severity of MDD symptoms. The 28-item Hamilton Depression Rating Scale was used to determine the primary outcome of 17-item HAM-D score. The HAM-D will serves as the primary outcome measure. HAM-D17 score ranges from 0 to 68. Higher score indicates more depressed symptom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Clinical Global Impression (CGI) Severity and Change Ratings Will be Secondary Outcome Measures.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Depressive Symptoms as Measured by the Beck Depression Inventory Will be a Secondary Outcome Measure.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sexual Function Will be a Secondary Outcome Measure.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Suicide Ideation as Determined by the Columbia Suicide Form Will be a Secondary Outcome Measure.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Side Effects Scale Will be Used to Assess Treatment-related Side Effects as a Secondary Outcome Measure.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Rhodiola rosea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herbal extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional anti-depressant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose monohydrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Herbal extract</intervention_name>
    <description>340-1,360 mg daily</description>
    <arm_group_label>Rhodiola rosea</arm_group_label>
    <other_name>Golden root</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>50-200 mg daily</description>
    <arm_group_label>Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactose monohydrate</intervention_name>
    <description>1-4 capsules daily</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Milk powder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women (all races and ethnicity) ≥ 18 years old

          -  DSM IV Axis I diagnosis of mild to moderate Major Depressive Disorder

          -  Baseline CGI/S rating of 3 ('mild') or 4 ('moderate')

          -  Baseline Hamilton Depression Rating score ≥ 10

          -  Not receiving other antidepressant therapy

          -  Able to provide signed informed consent

        Exclusion Criteria:

          -  Patients &lt; 18 years old

          -  Current primary DSM IV Axis I diagnosis other than Major Depressive Disorder

          -  CGI/S rating of 5 ('marked'), 6 ('severe') or 7 ('very severe')

          -  Actively suicidal or requiring hospitalization

          -  Uncontrolled medical condition

          -  Pregnant or nursing women

          -  Women of child-bearing potential not using a medically acceptable form of
             contraception

          -  Concurrent use of herbal remedies or mineral supplements [Note: Use of mineral
             supplements prescribed for medical purposes (e.g., osteoporosis) will not be
             excluded]

          -  Current use of chemotherapy or other medication (e.g., interferon) known to produce
             fatigue or mood changes

          -  Known sensitivity to R. rosea or sertraline

          -  History of non-response to sertraline in the current depressive episode
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun J. Mao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Research Unit</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.upenn.edu/dru</url>
    <description>University of Pennsylvania Depression Research Unit Website</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 4, 2016</lastchanged_date>
  <firstreceived_date>April 1, 2010</firstreceived_date>
  <firstreceived_results_date>July 20, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Antidepressant Therapy</keyword>
  <keyword>Herbal Treatment</keyword>
  <keyword>Rhodiola rosea</keyword>
  <keyword>Alternative Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There are actually 58 subjects who signed consents. However, one subject withdrew consent immediately after signed it due to change of mind. This subject didn't take any medication, therefore, only 57 subject received study intervention.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rhodiola Rosea</title>
          <description>Herbal extract
Herbal extract: 340-1,360 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Sertraline</title>
          <description>Conventional anti-depressant
Sertraline: 50-200 mg daily</description>
        </group>
        <group group_id="P3">
          <title>Sugar Pill</title>
          <description>Lactose monohydrate
Lactose monohydrate: 1-4 capsules daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rhodiola Rosea</title>
          <description>Herbal extract
Herbal extract: 340-1,360 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Sertraline</title>
          <description>Conventional anti-depressant
Sertraline: 50-200 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Sugar Pill</title>
          <description>Lactose monohydrate
Lactose monohydrate: 1-4 capsules daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.9" spread="16.9"/>
                    <measurement group_id="B2" value="41.4" spread="14.6"/>
                    <measurement group_id="B3" value="46.7" spread="15.2"/>
                    <measurement group_id="B4" value="45.0" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Depressive Symptoms as Measured by the Hamilton Depression Rating Scale (17-items) at Week 8 and Week 12.</title>
        <description>Hamilton Depression Rating Scale (HAM-D) is a validated, clinician-rated instrument for ascertaining the severity of MDD symptoms. The 28-item Hamilton Depression Rating Scale was used to determine the primary outcome of 17-item HAM-D score. The HAM-D will serves as the primary outcome measure. HAM-D17 score ranges from 0 to 68. Higher score indicates more depressed symptom.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rhodiola Rosea</title>
            <description>Herbal extract
Herbal extract: 340-1,360 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Sertraline</title>
            <description>Conventional anti-depressant
Sertraline: 50-200 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Lactose monohydrate
Lactose monohydrate: 1-4 capsules daily</description>
          </group>
        </group_list>
        <measure>
          <title>Depressive Symptoms as Measured by the Hamilton Depression Rating Scale (17-items) at Week 8 and Week 12.</title>
          <description>Hamilton Depression Rating Scale (HAM-D) is a validated, clinician-rated instrument for ascertaining the severity of MDD symptoms. The 28-item Hamilton Depression Rating Scale was used to determine the primary outcome of 17-item HAM-D score. The HAM-D will serves as the primary outcome measure. HAM-D17 score ranges from 0 to 68. Higher score indicates more depressed symptom.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAM-D17@WK8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="5.4"/>
                    <measurement group_id="O2" value="8.3" spread="4.5"/>
                    <measurement group_id="O3" value="8.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAM-D17@WK12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="6"/>
                    <measurement group_id="O2" value="7.8" spread="4.3"/>
                    <measurement group_id="O3" value="8.5" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Clinical Global Impression (CGI) Severity and Change Ratings Will be Secondary Outcome Measures.</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Depressive Symptoms as Measured by the Beck Depression Inventory Will be a Secondary Outcome Measure.</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sexual Function Will be a Secondary Outcome Measure.</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Suicide Ideation as Determined by the Columbia Suicide Form Will be a Secondary Outcome Measure.</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Emergent Side Effects Scale Will be Used to Assess Treatment-related Side Effects as a Secondary Outcome Measure.</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rhodiola Rosea</title>
          <description>Herbal extract
Herbal extract: 340-1,360 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Sertraline</title>
          <description>Conventional anti-depressant
Sertraline: 50-200 mg daily</description>
        </group>
        <group group_id="E3">
          <title>Sugar Pill</title>
          <description>Lactose monohydrate
Lactose monohydrate: 1-4 capsules daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jun Mao, Associate Professor</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-2481</phone>
      <email>jun.mao@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
